Studies on the different metabolic pathways of antipyrine in man. I. Oral administration of 250, 500 and 1000 mg to healthy volunteers
- PMID: 533575
- PMCID: PMC1429894
- DOI: 10.1111/j.1365-2125.1979.tb01040.x
Studies on the different metabolic pathways of antipyrine in man. I. Oral administration of 250, 500 and 1000 mg to healthy volunteers
Abstract
1 The plasma elimination rate of antipyrine, as measured by the salivary concentration decay, and the urinary excretion of antipyrine and its primary metabolites 4-hydroxy-antipyrine, norantipyrine, 3-hydroxymethyl-antipyrine and 3-carboxy-antipyrine was studied in five healthy volunteers, who received 250, 500 and 1000 mg antipyrine orally in a cross-over design.
2 The mean antipyrine half-life and metabolic clearance were 11.5 ± 2.5 h (range 10.2-16.9 h) and 3.4 ± 0.9 l/h (range 1.7-4.2 l/h) respectively after 500 mg. These values were not significantly different after 250 or 1000 mg (P > 0.1; paired t-test).
3 In 52 h urine 3.3 ± 1.2% of the dose of 500 mg antipyrine was excreted unchanged as antipyrine, 28.5 ± 2.2% as 4-hydroxy-antipyrine, 16.5 ± 6.0% as norantipyrine, 35.1 ± 7.2% as 3-hydroxymethyl-antipyrine and 3.3 ± 0.8% as 3-carboxy-antipyrine. The values obtained at the other dose levels were not significantly different (P > 0.1; paired t-test).
4 At all dose levels 4-hydroxy-antipyrine and norantipyrine were excreted in urine entirely as glucuronides. After 500 mg antipyrine, 3-hydroxymethyl-antipyrine was excreted as glucuronide to the extent of 58 ± 9% of the total excreted amount. This percentage was not significantly different at the other dose levels. 3-Carboxy-antipyrine was excreted in the free form at all three dose levels.
5 From 12 h of drug intake onwards, the urinary excretion rate curves of antipyrine and all its metabolites declined mono-exponentially with about the same half-life as the parent compound in saliva. The half-lives calculated from the excretion rate curves of 4-hydroxy-antipyrine, norantipyrine and 3-hydroxymethyl-antipyrine correlated significantly with the half-life of antipyrine in plasma. At all dose levels a relative delay in urinary excretion of 3-hydroxymethyl-antipyrine was observed compared to the urinary excretion of antipyrine and the other metabolites.
6 The ratios of the cumulative amounts of metabolites excreted in 24 h, were essentially the same as those measured in the 52 h samples.
Similar articles
-
Studies of the different metabolic pathways of antipyrine in man. Oral versus i.v. administration and the influence of urinary collection time.Eur J Clin Pharmacol. 1982;21(5):433-41. doi: 10.1007/BF00542332. Eur J Clin Pharmacol. 1982. PMID: 7075648
-
Pharmacokinetics and metabolism of antipyrine (phenazone) after intravenous and oral administration.Arzneimittelforschung. 1982;32(5):575-8. Arzneimittelforschung. 1982. PMID: 7201837 Clinical Trial.
-
Influence of thyroid status on plasma half-life of antipyrine in man.N Engl J Med. 1974 May 9;290(19):1040-2. doi: 10.1056/NEJM197405092901902. N Engl J Med. 1974. PMID: 4821905 No abstract available.
-
Unaltered metabolism of antipyrine and tolbutamide in fasting man.Clin Pharmacol Ther. 1975 Jun;17(6):650-6. doi: 10.1002/cpt1975176650. Clin Pharmacol Ther. 1975. PMID: 1139856
-
Multiple oral doses of diazepam, oxazepam and phenobarbital to dogs--behavioural effects and correlation with antipyrine half-life.Acta Pharmacol Toxicol (Copenh). 1977 Jan;40 Suppl 1(1):63-9. Acta Pharmacol Toxicol (Copenh). 1977. PMID: 300543
Cited by
-
Effects of alpha-interferon on theophylline pharmacokinetics and metabolism.Br J Clin Pharmacol. 1989 Jun;27(6):795-802. doi: 10.1111/j.1365-2125.1989.tb03442.x. Br J Clin Pharmacol. 1989. PMID: 2757895 Free PMC article. Clinical Trial.
-
The disposition of antipyrine and its metabolites in young and elderly healthy volunteers.Br J Clin Pharmacol. 1987 Jul;24(1):51-5. doi: 10.1111/j.1365-2125.1987.tb03135.x. Br J Clin Pharmacol. 1987. PMID: 3620285 Free PMC article.
-
Antipyrine metabolism in relation to polymorphic oxidations of sparteine and debrisoquine.Br J Clin Pharmacol. 1983 Mar;15(3):317-21. doi: 10.1111/j.1365-2125.1983.tb01505.x. Br J Clin Pharmacol. 1983. PMID: 6849767 Free PMC article.
-
Polymorphic 4-hydroxylation of debrisoquine in chronic discoid psoriasis.Eur J Clin Pharmacol. 1981;21(3):257-8. doi: 10.1007/BF00627929. Eur J Clin Pharmacol. 1981. PMID: 6895622 No abstract available.
-
Antipyrine metabolite formation in children in the acute phase of malnutrition and after recovery.Br J Clin Pharmacol. 1980 Oct;10(4):363-8. doi: 10.1111/j.1365-2125.1980.tb01772.x. Br J Clin Pharmacol. 1980. PMID: 7448107 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources